



Company Announcement no. 10/2009

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, April 16, 2009

Major Shareholder Announcement

Hørsholm, Denmark, April 16 2009; In accordance with Section 29 of the Securities Trading Act LifeCycle Pharma A/S (OMX: LCP) today announced that LCP has received a notification from ATP and ATP Invest that it after purchase has shareholdings in LCP of 2,873,215 shares of nom. DKK 1, corresponding to 5.09% of the share capital and the voting rights in LCP.

For more information, please contact:

LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose[®], can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.